Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Koeppen

Showing results (71-80 of 147) with videos related to

Pageof 15
Sort By:
The Oncologist|February 18, 2017
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal CancerJohanna C Bendell, Howard Hochster, Lowell L Hart, et al.
Cancer Discovery|November 9, 2019
Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15<sup>+</sup> Myofibroblasts as a Determinant of Patient Response to Cancer ImmunotherapyClaudia X Dominguez, Sören Müller, Shilpa Keerthivasan, et al.
Nature|March 31, 2017
A distinct role for Lgr5<sup>+</sup> stem cells in primary and metastatic colon cancerFelipe de Sousa e Melo, Antonina V Kurtova, Jonathan M Harnoss, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2022
Immune contexture of paediatric cancersMeghna Das Thakur, Carl J Franz, Laura Brennan, et al.
Plos One|February 13, 2014
Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancersErica B Schleifman, Rupal Desai, Jill M Spoerke, et al.
Nature|July 6, 2012
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitorsTimothy R Wilson, Jane Fridlyand, Yibing Yan, et al.
Breast Cancer Research and Treatment|October 23, 2014
Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samplesTimothy R Wilson, Yuanyuan Xiao, Jill M Spoerke, et al.
Nature Communications|December 16, 2021
Decoding non-canonical mRNA decay by the endoplasmic-reticulum stress sensor IRE1αAdrien Le Thomas, Elena Ferri, Scot Marsters, et al.
Nature Communications|November 5, 2020
Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancerMélanie Desbois, Akshata R Udyavar, Lisa Ryner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2015
Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of CapecitabineJoyce O'Shaughnessy, Hartmut Koeppen, Yuanyuan Xiao, et al.
Pageof 15

Showing results (71-80 of 147) with videos related to

Sort By:
Pageof 15
The Oncologist|February 18, 2017
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal CancerJohanna C Bendell, Howard Hochster, Lowell L Hart, et al.
Cancer Discovery|November 9, 2019
Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15<sup>+</sup> Myofibroblasts as a Determinant of Patient Response to Cancer ImmunotherapyClaudia X Dominguez, Sören Müller, Shilpa Keerthivasan, et al.
Nature|March 31, 2017
A distinct role for Lgr5<sup>+</sup> stem cells in primary and metastatic colon cancerFelipe de Sousa e Melo, Antonina V Kurtova, Jonathan M Harnoss, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2022
Immune contexture of paediatric cancersMeghna Das Thakur, Carl J Franz, Laura Brennan, et al.
Plos One|February 13, 2014
Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancersErica B Schleifman, Rupal Desai, Jill M Spoerke, et al.
Nature|July 6, 2012
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitorsTimothy R Wilson, Jane Fridlyand, Yibing Yan, et al.
Breast Cancer Research and Treatment|October 23, 2014
Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samplesTimothy R Wilson, Yuanyuan Xiao, Jill M Spoerke, et al.
Nature Communications|December 16, 2021
Decoding non-canonical mRNA decay by the endoplasmic-reticulum stress sensor IRE1αAdrien Le Thomas, Elena Ferri, Scot Marsters, et al.
Nature Communications|November 5, 2020
Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancerMélanie Desbois, Akshata R Udyavar, Lisa Ryner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2015
Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of CapecitabineJoyce O'Shaughnessy, Hartmut Koeppen, Yuanyuan Xiao, et al.
Pageof 15